|
[1]
|
中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年, 修订版) [J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 106-129.
|
|
[2]
|
Luo, X., Hua, Z.X., Zhang, Y.N., et al. (2024) Review of the Development and Latest Perspectives in 2024 on Allergic Rhinitis and Its Impact on Asthma (ARIA). Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 59, 1107-1114.
|
|
[3]
|
Noon, L. (1911) Prophylactic Inoculation against Hay Fever. The Lancet, 177, 1572-1573. [Google Scholar] [CrossRef]
|
|
[4]
|
Frew, A.J. (2011) Hundred Years of Allergen Immunotherapy. Clinical & Experimental Allergy, 41, 1221-1225. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Huang, J., Zhang, W., Xiang, R., Tan, L., Liu, P., Tao, Z., et al. (2023) The Early-Phase Transcriptome and the Clinical Efficacy Analysis in Three Modes of Subcutaneous Immunotherapy for Allergic Rhinitis. World Allergy Organization Journal, 16, Article 100811. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
王玲, 高亚东, 王永博, 董翔. 变应原皮下特异性免疫治疗依从率及影响因素的系统评价与Meta分析[J]. 中华临床免疫和变态反应杂志, 2024, 18(2): 148-156.
|
|
[7]
|
Greiwe, J. and Bernstein, J.A. (2022) Accelerated/Rush Allergen Immunotherapy. Allergy and Asthma Proceedings, 43, 344-349. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Jiang, Y.L. and Zhu, X.H. (2018) Research on Immune Regulation Mechanism of Immunotherapy for Allergic Rhinitis. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 32, 1440-1443.
|
|
[9]
|
Cox, L. (2006) Accelerated Immunotherapy Schedules: Review of Efficacy and Safety. Annals of Allergy, Asthma & Immunology, 97, 126-138. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Lee, M.C., Puglisi, L.B. and Kelso, J.M. (2023) Comparison of Standard, Cluster, and Rush Allergy Immunotherapy Buildup Protocols. The Journal of Allergy and Clinical Immunology: In Practice, 11, 2884-2889. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Rodríguez Plata, E., Hernández Santana, G.L., Cubas Mesa, E., Coello Valeriano, K., Matas Ros, M. and Buendía Jiménez, I. (2021) Real-Life Safety Study of an Accelerated Cluster Immunotherapy with a House Dust Mite Native Extract in Patients with Allergic Rhinitis or Rhinoconjunctivitis. Allergo Journal International, 30, 259-260. [Google Scholar] [CrossRef]
|
|
[12]
|
Quiralte, J., Justicia, J.L., Cardona, V., Dávila, I., Moreno, E., Ruiz, B., et al. (2013) Is Faster Safer? Cluster versus Short Conventional Subcutaneous Allergen Immunotherapy. Immunotherapy, 5, 1295-1303. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Wang, C.S., Wang, X.D., Zhang, W., et al. (2012) Long-Term Efficacy of Dermatophagoides Pteronyssinus Immunotherapy in Patients with Allergic Rhinitis: A 3-Year Prospective Study. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 47, 804-808.
|
|
[14]
|
Jutel, M., Klimek, L., Richter, H., Brüggenjürgen, B. and Vogelberg, C. (2024) House Dust Mite SCIT Reduces Asthma Risk and Significantly Improves Long‐Term Rhinitis and Asthma Control—A RWE Study. Allergy, 79, 1042-1051. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Senti, G. and Kündig, T.M. (2015) Intralymphatic Immunotherapy. World Allergy Organization Journal, 8, Article 9. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Johansen, P., Häffner, A.C., Koch, F., Zepter, K., Erdmann, I., Maloy, K., et al. (2005) Direct Intralymphatic Injection of Peptide Vaccines Enhances Immunogenicity. European Journal of Immunology, 35, 568-574. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Martínez-Gómez, J.M., Johansen, P., Erdmann, I., Senti, G., Crameri, R. and Kündig, T.M. (2009) Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy. International Archives of Allergy and Immunology, 150, 59-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Senti, G., Prinz Vavricka, B.M., Erdmann, I., Diaz, M.I., Markus, R., McCormack, S.J., et al. (2008) Intralymphatic Allergen Administration Renders Specific Immunotherapy Faster and Safer: A Randomized Controlled Trial. Proceedings of the National Academy of Sciences, 105, 17908-17912. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Hylander, T., Latif, L., Petersson-Westin, U. and Cardell, L.O. (2013) Intralymphatic Allergen-Specific Immunotherapy: An Effective and Safe Alternative Treatment Route for Pollen-Induced Allergic Rhinitis. Journal of Allergy and Clinical Immunology, 131, 412-420. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Chabot, A., Senti, G., Erdmann, I., Prinz, B.M., Wüthrich, B., Šošić, L., et al. (2022) Intralymphatic Immunotherapy (ILIT) with Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans. Frontiers in Allergy, 3, Article 832010. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Adlany, Y.K., Šošić, L., Senti, G., Lang, C.C.V., Wüthrich, B., Kündig, T.M., et al. (2023) Quality of Life in Allergic Rhinitis Patients Treated with Intralymphatic Immunotherapy (ILIT): A 19-Year Follow-Up. Journal of Allergy and Clinical Immunology: Global, 2, 43-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Senti, G., Crameri, R., Kuster, D., Johansen, P., Martinez-Gomez, J.M., Graf, N., et al. (2012) Intralymphatic Immunotherapy for Cat Allergy Induces Tolerance after Only 3 Injections. Journal of Allergy and Clinical Immunology, 129, 1290-1296. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Hylander, T., Larsson, O., Petersson-Westin, U., Eriksson, M., Kumlien Georén, S., Winqvist, O., et al. (2016) Intralymphatic Immunotherapy of Pollen-Induced Rhinoconjunctivitis: A Double-Blind Placebo-Controlled Trial. Respiratory Research, 17, Article 10.
|
|
[24]
|
Kündig, T.M., Johansen, P., Bachmann, M.F., Cardell, L.O. and Senti, G. (2014) Intralymphatic Immunotherapy: Time Interval between Injections Is Essential. Journal of Allergy and Clinical Immunology, 133, 930-931. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Khoshkhui, M., Jabbari, F., Zargar, F.S., Motevalli Haghi, N.S. and Ariaee, N. (2024) Fluctuation of Disease Severity and Quality of Life Applying Intra-Lymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis. Iranian Journal of Allergy, Asthma and Immunology, 23, 149-157. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Wang, Q., Wang, K., Qin, Y., Huang, W., Li, Y., Yu, Q., et al. (2023) Intra-Cervical Lymphatic Immunotherapy for Dust Mite-Induced Allergic Rhinoconjunctivitis in Children: A 3-Year Prospective Randomized Controlled Trial. Frontiers in Immunology, 14, Article 1144813. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
王凯, 王跃建, 肖平, 等. 颈部淋巴结内特异性免疫治疗变应性鼻炎疗效及安全性的研究[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(5): 432-436.
|
|
[28]
|
王凯, 秦扬, 王启幸, 等. 成人变应性鼻炎经颈部淋巴结内免疫治疗远期疗效的随机对照研究[J]. 中华耳鼻咽喉头颈外科杂志, 2023, 58(9): 871-877.
|
|
[29]
|
Scadding, G.K. and Brostoff, J. (1986) Low Dose Sublingual Therapy in Patients with Allergic Rhinitis Due to House Dust Mite. Clinical & Experimental Allergy, 16, 483-491. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Tankersley, M., Han, J.K. and Nolte, H. (2020) Clinical Aspects of Sublingual Immunotherapy Tablets and Drops. Annals of Allergy, Asthma & Immunology, 124, 573-582. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Klimek, L., Brehler, R., Casper, I., Klimek, F., Hagemann, J., Cuevas, M., et al. (2023) Allergen Immunotherapy in House Dust Mite-Associated Allergic Rhinitis: Efficacy of the 300 IR Mite Tablet. Allergo Journal International, 32, 10-17. [Google Scholar] [CrossRef]
|
|
[32]
|
Gotoh, M., Maekawa, Y., Saito, S., Kato, N., Horikawa, E. and Nishino, N. (2024) Real-World Surveillance of Standardized Quality (SQ) House Dust Mite Sublingual Immunotherapy Tablets for 3 Years in Japan. Allergy and Asthma Proceedings, 46, 59-69. [Google Scholar] [CrossRef]
|
|
[33]
|
Marogna, M., Spadolini, I., Massolo, A., Canonica, G.W. and Passalacqua, G. (2010) Long-Lasting Effects of Sublingual Immunotherapy According to Its Duration: A 15-Year Prospective Study. Journal of Allergy and Clinical Immunology, 126, 969-975. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Passalacqua, G., Bagnasco, D. and Canonica, G.W. (2019) 30 Years of Sublingual Immunotherapy. Allergy, 75, 1107-1120. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Nelson, H., Bernstein, D., Biedermann, T. and Nolte, H. (2023) Efficacy of Sublingual Immunotherapy Tablets for Allergic Rhinoconjunctivitis in Adult Monosensitized and Polysensitized Subjects. Journal of Allergy and Clinical Immunology, 151, AB124. [Google Scholar] [CrossRef]
|
|
[36]
|
Hoshino, M., Akitsu, K., Ohtawa, J. and Kubota, K. (2024) Long-Term Efficacy of House Dust Mite Sublingual Immunotherapy on Clinical and Pulmonary Function in Patients with Asthma and Allergic Rhinitis. Journal of Allergy and Clinical Immunology: Global, 3, Article 100206. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Owenier, C., Barnowski, C., Leineweber, M., Yu, D., Verhagen, M. and Distler, A. (2023) Tolerability and Safety of Sublingual Immunotherapy in Patients with Tree Pollen Allergy in Daily Practice—An Open, Prospective, Non-Interventional Study. Journal of Clinical Medicine, 12, Article 5517. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Okamoto, Y., Kato, M., Ishii, K., Sato, Y., Hata, T. and Asaka, Y. (2023) Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan. Immunotherapy, 15, 1401-1414. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Sasamoto, K., Nagakura, K., Asaumi, T., Fusayasu, N., Ohashi‐Doi, K., Yanagida, N., et al. (2024) Efficacy and Safety of Sublingual Immunotherapy Using House Dust Mite Tablet for 1-4 Years Old Children with Perennial Allergic Rhinitis. Pediatric Allergy and Immunology, 35, e14203. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
孙楚东, 郝钧, 罗丽华, 等. 皮下免疫与舌下免疫治疗变应性鼻炎的临床疗效分析[J]. 标记免疫分析与临床, 2020, 27(6): 957-961.
|
|
[41]
|
赵艳, 何荆培, 赵喜桂, 等. 皮下免疫和舌下免疫治疗变应性鼻炎的有效性及安全性[J]. 中国实用医药, 2020, 15(3): 153-155.
|
|
[42]
|
Hamada, M., Saeki, K. and Tanaka, I. (2023) Comparison of Rush-Subcutaneous and Sublingual Immunotherapy with House Dust Mite Extract for Pediatric Allergic Rhinitis: A Prospective Cohort Study. Allergology International, 72, 573-579. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Pongdee, T. and Li, J.T. (2024) Omalizumab Safety Concerns. The Journal of Allergy and Clinical Immunology, 155, 31-35.
|
|
[44]
|
Shen, W., Zhou, Q., Zhang, Q., Han, L., Chen, L., Li, X., et al. (2024) Efficacy and Safety of Omalizumab Combined with Allergen Immunotherapy in Children with Moderate to Severe Allergic Asthma. International Forum of Allergy & Rhinology, 15, 208-211. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Antosz, K., Batko, J., Błażejewska, M., Gawor, A., Sleziak, J. and Gomułka, K. (2024) Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases. Biomedicines, 12, Article 1531. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
AbuJabal, R., Ramakrishnan, R.K., Bajbouj, K. and Hamid, Q. (2024) Role of il‐5 in Asthma and Airway Remodelling. Clinical & Experimental Allergy, 54, 538-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Shirley, M. (2017) Dupilumab: First Global Approval. Drugs, 77, 1115-1121. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Layritz, A., Galicia‐Carreón, J., Benfadal, S. and Novak, N. (2023) Differences in Allergen‐Specific Basophil Activation and T Cell Proliferation in Atopic Dermatitis Patients with Comorbid Allergic Rhinoconjunctivitis Treated with a Monoclonal Anti‐IL‐4Rα Antibody or Allergen‐Specific Immunotherapy. Immunity, Inflammation and Disease, 11, e808. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
von Bubnoff, D., Sell, U., Arriens, S., Specht, S., Hoerauf, A. and Bieber, T. (2012) Differential Expression of Toll-Like Receptor 2 on Dendritic Cells from Asymptomatic and Symptomatic Atopic Donors. International Archives of Allergy and Immunology, 159, 41-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Kirtland, M.E., Tsitoura, D.C., Durham, S.R. and Shamji, M.H. (2020) Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. Frontiers in Immunology, 11, Article 599083. [Google Scholar] [CrossRef] [PubMed]
|